A Multi-centre, Open-label, Parallel-group Study Investigating the Pharmacokinetics, Safety and Tolerability After a Single Dose of Oral Etavopivat in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Participants With Normal Hepatic Function
Latest Information Update: 01 Oct 2025
At a glance
- Drugs Etavopivat (Primary)
- Indications Myelodysplastic syndromes; Sickle cell anaemia; Thalassaemia
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
Most Recent Events
- 10 Jun 2024 Planned End Date changed from 4 Jul 2025 to 4 Sep 2025.
- 10 Jun 2024 Planned primary completion date changed from 4 Jul 2025 to 4 Sep 2025.
- 10 Jun 2024 Status changed from not yet recruiting to recruiting.